Compare CPSH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | TENX |
|---|---|---|
| Founded | 1984 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 56.2M |
| IPO Year | 1995 | 2001 |
| Metric | CPSH | TENX |
|---|---|---|
| Price | $3.62 | $15.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $29.67 |
| AVG Volume (30 Days) | 150.9K | ★ 386.9K |
| Earning Date | 03-02-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.64 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.41 | N/A |
| Revenue Next Year | $20.16 | N/A |
| P/E Ratio | $126.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $4.64 |
| 52 Week High | $6.85 | $18.38 |
| Indicator | CPSH | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 59.84 |
| Support Level | $3.61 | $11.29 |
| Resistance Level | $4.41 | $16.27 |
| Average True Range (ATR) | 0.27 | 1.25 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 20.55 | 70.39 |
CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.